A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Summary

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Eligibility

Key Inclusion Criteria:

* Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
* Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evidence of breast cancer recurrence or progression during or within 12 months from the end of or during adjuvant treatment with endocrine therapy, as these participants are considered as first-line relapsed participants. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required. No other therapeutic options are considered appropriate by the investigator.
* Up to 6 prior lines of systemic therapy (including up to 2 prior lines consisting of chemotherapy, cytotoxic antibody drug conjugate, or a combination of both regimens) are allowed in the advanced/metastatic setting.
* Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.

Key Exclusion Criteria:

* Active or newly diagnosed central nervous system metastases.
* Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%.

Note: Other inclusion/exclusion criteria may apply.

Conditions3

Interventions2

Locations32 sites

Find trials near these locations

Related trials

• A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer — Gustave Roussy, Cancer Campus, Grand Paris
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — MedSIR
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer — SOLTI Breast Cancer Research Group
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) — European Organisation for Research and Treatment of Cancer - EORTC
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC — West German Study Group
• Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC — SciClone Pharmaceuticals
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Stemline Therapeutics, Inc.
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — Stemline Therapeutics, Inc.

Browse More Trials